AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Imugene Ltd (ASX:IMU)
0.046 AUD
-0.002 4.167%Sponsored Reports
Loading...
| Previous Close (in AUD) | 0.048 |
|---|---|
| Change | -0.002 4.167% |
| 52 W H/L (in AUD) | 0.150/0.043 |
| EBITDA (in AUD) | -137.447M |
| PE Ratio | -- |
| Volume | 8603585 |
| Diluted Eps TTM | -0.02 |
| Total Assets (in AUD) | 151.398M |
|---|---|
| Total Liabilities (in AUD) | 33.143M |
| Revenue TTM (in AUD) | 4.97M |
| Cash (in AUD) | 93.108M |
| Market Cap (in AUD) | 340.519 M |
| Revenue Per Share TTM | 0.001 |
| Gross Profit TTM (in AUD) | 11.778M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Imugene Ltd
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy CHECKvacc in phase 1 clinical trial for triple negative breast cancer; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic and advanced gastric cancer; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. The company has a research collaboration with NeoImmuneTech to enhance cancer treatments. Imugene Limited is based in Sydney, Australia.
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD | Exec. Chairman | 1956 |
| 2. | Ms. Leslie Chong | CEO, MD & Exec. Director | NA |
| 3. | Dr. Nicholas J. Ede B.Sc.(Hons.), Ph.D. | Chief Technology Officer | NA |
| 4. | Dr. Monil Shah M.B.A., Pharm.D. | Chief Bus. Officer | NA |
| 5. | Mr. Michael Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICD | Chief Financial Officer | 1966 |
| 6. | Ms. Ursula McCurry | Sr. VP of Clinical Operations | NA |
| 7. | Dr. Giovanni Selvaggi | Chief Medical Officer | NA |
| 8. | Mr. Nathan Jong C.A. | Joint Company Sec. | NA |
| 9. | Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD | Executive Chairman | 1956 |
| 10. | Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD | Executive Chairman | 1956 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (AUD) | Price (AUD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
CSL
CSL Ltd |
-1.120 0.391% | 285.5 | 34.180 | 33.670 | 9.272 | 5.246 | 6.905 | 21.431 |
|
TLX
Telix Pharmaceuticals Ltd |
-0.490 2.088% | 23.25 | 154.400 | 66.225 | 12.005 | 18.939 | 11.858 | 103.530 |
|
CU6
Clarity Pharmaceuticals Ltd |
-0.400 5.362% | 7.46 | 0.000 | 0.000 | 195.076 | 16.087 | 0.000 | -0.779 |
|
NEU
Neuren Pharmaceuticals Ltd |
-0.490 2.877% | 16.94 | 15.000 | 35.211 | 9.687 | 5.185 | 6.562 | 8.553 |
Income Statement
(Currency in AUD)| Breakdown | 30-06-2023 | 30-06-2022 | 30-06-2021 | 30-06-2020 | 30-06-2019 |
|---|---|---|---|---|---|
| Income Before Tax | -39.171M | -37.869M | -18.455M | -10.508M | -7.775M |
| Minority Interest | - | - | - | - | - |
| Net Income | -39.171M | -37.976M | -25.767M | -14.587M | -7.776M |
| Selling General Administrative | 17.766M | 12.097M | 9.438M | 4.293M | 3.806M |
| Gross Profit | - | - | - | - | 4.127M |
| Reconciled Depreciation | 0.19M | 0.203M | 0.104M | 0.082M | 0.063M |
| Ebit | -51.291M | -37.658M | -18.344M | -10.503M | -7.769M |
| Ebitda | -51.1M | -37.454M | -18.24M | -10.42M | -7.706M |
| Depreciation And Amortization | 0.19M | 0.203M | 0.104M | 0.082M | 0.063M |
| Operating Income | -51.291M | -37.658M | -18.344M | -10.503M | -7.769M |
| Other Operating Expenses | 51.293M | 50.673M | 25.666M | 14.879M | 12.389M |
| Interest Expense | - | 0.107M | 0.111M | 0.005M | 0.006M |
| Tax Provision | 0M | 0M | 0M | 0M | 0M |
| Interest Income | 1.88M | 0.192M | 0.127M | 0.297M | 0.415M |
| Net Interest Income | 1.852M | 0.072M | 0.011M | 0.297M | 0.409M |
| Income Tax Expense | -1.85M | 0.107M | 7.311M | 4.079M | 0M |
| Total Revenue | - | 0M | 0M | 4.21M | 4.542M |
| Total Operating Expenses | 51.293M | 50.673M | 25.666M | 14.879M | 12.389M |
| Cost Of Revenue | - | - | - | - | - |
| Total Other Income Expense Net | 10.27M | -0.212M | -0.111M | -0.005M | -0.006M |
| Net Income From Continuing Ops | -39.171M | -37.869M | -18.455M | -10.508M | -7.775M |
| Net Income Applicable To Common Shares | -37.915M | -37.869M | -18.455M | -10.508M | -7.775M |
Balance Sheet
(Currency in AUD)| Breakdown | 30-06-2024 | 30-06-2023 | 30-06-2022 | 30-06-2021 | 30-06-2020 |
|---|---|---|---|---|---|
| Total Assets | 151.398M | 195.807M | 147.606M | 71.809M | 65.205M |
| Intangible Assets | 34.12M | 30.486M | 32.689M | 34.893M | 30.458M |
| Other Current Assets | 7.308M | 0.402M | 1.11M | 0.17M | 0.194M |
| Total Liab | 33.143M | 7.437M | 8.901M | 6.791M | 5.399M |
| Total Stockholder Equity | 118.254M | 188.37M | 138.705M | 65.018M | 59.806M |
| Other Current Liab | 22.418M | 1.923M | 1.423M | 2.853M | 1.435M |
| Common Stock | 370.313M | 314.402M | 230.789M | 113.107M | 92.798M |
| Capital Stock | 370.313M | 314.402M | 230.789M | 113.107M | 104.895M |
| Retained Earnings | -289.832M | -142.692M | -103.521M | -65.652M | -47.31M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 0.019M | 0.035M | 0.016M | 0.016M |
| Cash | 93.108M | 153.151M | 99.888M | 29.487M | 30.107M |
| Cash And Equivalents | - | 49.543M | 29M | 21.001M | 25.001M |
| Total Current Liabilities | 29.299M | 6.084M | 7.425M | 4.457M | 2.899M |
| Current Deferred Revenue | - | 1.629M | 1.304M | 0.738M | 0.391M |
| Net Debt | -91.561M | -152.597M | -99.214M | -29.216M | -30.037M |
| Short Term Debt | 0.912M | 0.191M | 0.184M | 0.106M | 0.061M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 1.547M | 0.553M | 0.673M | 0.271M | 0.069M |
| Other Stockholder Equity | - | -172.966M | -127.268M | -47.455M | -45.487M |
| Property Plant Equipment | - | 0.683M | 0.863M | 0.466M | 0.156M |
| Total Current Assets | 113.034M | 164.401M | 113.766M | 36.319M | 34.495M |
| Long Term Investments | 2.413M | 0.218M | 0.252M | 0.115M | 0.081M |
| Short Term Investments | 1.435M | - | -0M | - | - |
| Net Receivables | 12.619M | 10.849M | 12.768M | 6.662M | 4.194M |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 5.968M | 2.341M | 4.513M | 0.76M | 1.013M |
| Accumulated Other Comprehensive Income | 37.773M | 16.66M | 11.437M | 17.563M | 14.319M |
| Non Currrent Assets Other | 0.133M | 0.019M | 0.035M | 0.016M | 0.016M |
| Non Current Assets Total | 38.364M | 31.405M | 33.84M | 35.49M | 30.71M |
| Capital Lease Obligations | - | 0.553M | 0.673M | 0.271M | 0.069M |
| Long Term Debt Total | - | 0.362M | 0.489M | 0.165M | 0.008M |
Cash Flow
(Currency in AUD)| Breakdown | 30-06-2023 | 30-06-2022 | 30-06-2021 | 30-06-2020 | 30-06-2019 |
|---|---|---|---|---|---|
| Investments | 1.889M | -0.137M | -0.035M | -0.031M | -0.03M |
| Total Cashflows From Investing Activities | 1.889M | -0.221M | -5.326M | -1.207M | 0.247M |
| Total Cash From Financing Activities | 82.981M | 101.341M | 17.985M | 22.707M | 18.773M |
| Net Income | -37.915M | -37.869M | -18.455M | -10.508M | -7.776M |
| Change In Cash | 53.263M | 70.401M | -0.62M | 11.059M | 11.226M |
| Begin Period Cash Flow | 99.888M | 29.487M | 30.107M | 19.048M | 7.822M |
| End Period Cash Flow | 153.151M | 99.888M | 29.487M | 30.107M | 19.048M |
| Total Cash From Operating Activities | -31.471M | -30.848M | -13.28M | -10.438M | -7.909M |
| Depreciation | 2.393M | 2.407M | 1.962M | 0.082M | 0.063M |
| Other Cashflows From Investing Activities | 1.889M | 0.174M | 0.156M | 0.311M | 0.405M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | -5.042M | -6.151M | -0.126M | -1.801M | -1.444M |
| Other Cashflows From Financing Activities | -0.147M | -1.385M | 0.063M | -0.059M | -0.047M |
| Capital Expenditures | 0M | 0.277M | 5.448M | 1.487M | 0.144M |
| Change In Working Capital | 1.089M | -6.108M | -2.455M | -0.034M | 1.868M |
| Other Non Cash Items | 4.051M | 4.614M | 3.213M | -0.012M | 7.712M |
| Free Cash Flow | -31.471M | -31.125M | -18.728M | -11.924M | -8.053M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | DFA International Sustainability Core 1 Portfolio | 3 years ago | 1293602 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Related Articles
Loading...
